BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
9/22/2026 3:20:35 AM | Browse: 59 | Download: 234
| ISSN |
1007-9327 (print) and 2219-2840 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
©Author(s) (or their employer(s)) 2026. No commercial re-use. See Permissions. Published by Baishideng Publishing Group Inc. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Gastroenterology & Hepatology |
| Manuscript Type |
Observational Study |
| Article Title |
Real-world effectiveness and safety of risankizumab in multirefractory Crohn’s disease: A multicenter AIRIS-Crohn registry analysis
|
| Manuscript Source |
Invited Manuscript |
| All Author List |
Antonio M Caballero-Mateos, Teresa Valdés-Delgado, Raúl Olmedo-Martín, Patricia Romero-Cara, María del Mar Martín-Rodríguez, Ana Lancho Muñoz, Melody Moreno-Barrueco, Raúl Gijón-Villanova, Nuria Fernández-Moreno, Francisco J Rodríguez-González, Álvaro Hernández-Martínez, Ana María Trapero-Martínez, Ana Bejarano-García, José Manuel Benitez Cantero, Francisco J Mata-Perdigón, Antonia Sáez-Díaz and Federico Argüelles-Arias |
| ORCID |
|
| Funding Agency and Grant Number |
|
| Corresponding Author |
Teresa Valdés-Delgado, Department of Gastroenterology, Virgen Macarena University Hospital, Dr. Fedriani, Seville 41009, Spain. teresavaldes4@hotmail.com |
| Key Words |
Crohn’s disease; Inflammatory bowel disease; Risankizumab; Real-world evidence; Interleukin-12/23 |
| Core Tip |
Risankizumab, a selective interleukin-23p19 inhibitor, emerges as a promising therapeutic option for patients with multirefractory Crohn’s disease. This multicenter real-world study of 205 patients demonstrates that risankizumab rapidly achieves clinical remission (49% at week 12) and maintains steroid-free remission in over 40% of patients throughout one-year follow-up. The excellent safety profile and high treatment persistence (> 90%) establish interleukin-23 blockade as a key strategy for patients with limited biologic alternatives in routine clinical practice. |
| Publish Date |
2026-09-22 03:20 |
| Citation |
Caballero-Mateos AM, Valdés-Delgado T, Olmedo-Martín R, Romero-Cara P, Martín-Rodríguez MDM, Lancho Muñoz A, Moreno-Barrueco M, Gijón-Villanova R, Fernández-Moreno N, Rodríguez-González FJ, Hernández-Martínez Á, Trapero-Martínez AM, Bejarano-García A, Benitez Cantero JM, Mata-Perdigón FJ, Sáez-Díaz A, Argüelles-Arias F. Real-world effectiveness and safety of risankizumab in multirefractory Crohn’s disease: A multicenter AIRIS-Crohn registry analysis. World J Gastroenterol 2026; 32(42): 119693
|
| URL |
https://www.wjgnet.com/1007-9327/full/v32/i42/119693.htm |
| DOI |
https://doi.org/10.3748/wjg.119693 |
Copyright © 1993-2026 Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA. All rights reserved, including rights relating to text and data mining, AI training, and similar technologies. For open-access content, the applicable copyright and licensing terms govern.